Application
SB 204741 has been used as a 5-hydroxytryptamine receptor 2B (Htr2B) antagonist:
- to inhibit Htr2b signaling to test its effect on hepatic stellate cell (HSC) activation in three-month-old adult zebrafish
- to test its effect on the inhibition of fluoxetine effects in depressive-like behavioral studies in mice
- to test its effect in reducing scratching behavior evoked by sertraline in mice
Biochem/physiol Actions
SB 204741 reduces the synaptic facilitation induced by the low dose of buprenorphine in spinal C-fiber synapses.
5-HT2B serotonin receptor antagonist.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from GlaxoSmithKline
- UPC:
- 85111616
- Condition:
- New
- HazmatClass:
- No
- MPN:
- S0693-10MG
- CAS:
- 152239-46-8
akash.verma@cenmed.com
(732) 447-1115





